



# MEDTECHAI

Confidential | 2021

Partners with **Oxford Immune Algorithmics (OIA)**



The AI that learns from  
and monitors your  
immune system

Delivering personalized  
and predictive medicine  
for you

M E D T E C H A I . I O

# FORWARD LOOKING INFORMATION

This Presentation contains "forward-looking information" within the meaning of applicable Canadian securities laws ("forward-looking statements"), concerning the business, operations and financial performance and condition of the Company. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this Presentation. Generally, any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will be taken", "occur" or "be achieved") are not statements of historical fact and may be forward-looking statements.

Forward-looking statements are not guarantees of future performance and are based on the opinions, estimates and assumptions of management as of the date such statements are made, which management believes to be reasonable, including without limitation, regarding: financial projections and budgets anticipated costs and expenditures. Many assumptions are based on factors and events that are not within the control of the Company and there is no assurance they will prove to be correct.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, conditions, level of activity, performance or achievements of Oxford Immune Algorithmics (OIA) to be materially different from those expressed or implied by such forward-looking statements, including, without limitation: the impact of global supply chain and financial market disruptions as a result of the ongoing COVID-19 crisis; additional financing requirements; delays in, or inability to achieve, planned commercial production changes or disruptions in the securities markets; risks associated with completion of the concurrent private placement; risks from the need for additional capital and the Company's ability to raise additional funds; adequacy of financial resources; the introduction of new taxes or changes in tax laws and interpretations; risks related to political and economic instability in the United Kingdom or anywhere else where the company may operate; and additional risk factors discussed in this Presentation. Should one or more

of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of the corporation, or industry results, may vary materially from those described in this Presentation. Furthermore, the recent world-wide pandemic relating to the COVID-19 virus has had a material and adverse affect on the world economy. The future impact of this outbreak is highly uncertain and cannot be predicted and there is no assurance that the outbreak will not have a material adverse impact on the future results of OIA.

Although management has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not the times at or by which such performance or results will be achieved. Except as expressly required by applicable Canadian securities law, the Company assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements in this presentation are qualified by these cautionary statements.

- **MedTechAI** is the financing arm of Oxford Immune Algorithmics (OIA)
- **MedTechAI** owns 28% of OIA. Financing to acquire another 10% equals ownership of 38% of OIA
- **OIA**, the creators of **Algocyte**, have scholarly roots at top global research institutions.
- Originated at **Karolinska\***, incubated by **the University Oxford**, and co-developed with **the University of Cambridge**
- **MedTechAI** owns **70% of Algocyte Canada**



\*Awarding institution of the Nobel Prize in Physiology or Medicine

CONFIDENTIAL

MEDTECHAI

# OIA

## THE FOUNDER



Dr. Hector Zenil | Founder & CEO  
MSc, PhD CompSci, PhD Phil

Elected Member of London's  
Mathematical Society

MEDTECHAI

CONFIDENTIAL

- Worked as creative right-hand of CEO of the leading mathematical software company **Wolfram Research**
- Wrote code for the AI engine behind **Siri's** and **Alexa's** factual answering machine
- Lab leader at the Unit of Computational Medicine at the **Karolinska Institute** (the institution that awards the Nobel Prize in Medicine)
- **NASA** Payload team member at MIT for the Mars Gravity Biosatellite to test health effects of artificial microgravity on mammals
- Senior researcher and faculty member at the **University of Oxford**
- UK's National Advisor on Artificial Intelligence at the **Alan Turing Institute / British Library / OECD**
- More than **20 years experience** in industry and academia in **6 countries**

> 100 papers, ~ 10 books published by  
Cambridge University Press / Springer  
Nature / Imperial College Press



With foreword by Sir  
Roger Penrose, Nobel  
Prize in Physics 2020 and  
thesis advisor of Stephen  
Hawking

# +250 papers published in the last 10 years

Experts and pioneers with more than 250 papers in top-ranked journals in the areas of:

Immunology | Artificial Intelligence | Molecular Biology  
Computational Medicine | Genetic Networks

WITH OVER 10K CITATIONS



**Dr. Hector Zenil**

- Oxford Computer Scientist
- OIA's CEO | Founder



**Dr. Jurgen Riedel**

- Hamburg's Physicist
- OIA's Chief Technology Officer  
Co-Founder






**Dr. Kourosh Saeb-Parsy**

- Professor of Transplantation  
at Cambridge University Hospital
- OIA's Chief Medical Officer

CONFIDENTIAL

MEDTECHAI



## OIA/Algocyte:

Transforming the "medicine of what" to the "medicine of why"

### Purpose (Why does OIA exist?)

Combining AI and Technology to provide precise, predictive and personalized valued-based medicine, focused on causal diagnostics.

### Mission (What we do)

Apply artificial intelligence to mimic and enhance human medical reasoning to monitor our immune system.

### Values (How we do it)

Innovative, Disruptive, Excellence Focused, Trustworthy & Patient-centric.

### Vision (Where we are going)

Provide precise and personalized medicine to create a world free of preventable diseases



ISO 13485:2016



DCB 0129

Assured by SAFE HAND



ISO 14971:2019




ISO 27001:2013





# OIA's Secret Sauce:

## AI Augmentation process



Off the shelf  
electronics


Cutting-edge  
optics &  
computer vision

Human-like reasoning  
A.I.  
> 10y of research\*

\* OIA's Artificial Reasoning  
Technology (explainable,  
traceable) away from  
traditional AI black boxes

Precise,  
Personalized &  
Predictive  
Medicine


# OIA: Medical Device + AI Diagnostic Platform (Algocyte)



## Revenue Model: Device + Proprietary Consumables

- Cell abnormality (cancer, malaria, sickle cell)
- Red blood count (anemia)
- White blood cell differential (viral & bacterial infections)
- Cell viability (e.g. drug treatment)
- Immune strength to pathogens (e.g. HIV, COVID19)

CE  
Algocyte: Clinician-driven & input-agnostic platform




## Intuitive AI diagnostics

- CE marked in the EU and UK as a Medical Device (FDA in process)
- Device/input agnostic (universal data exchange through HL7)
- Score-based patient triaging and automation of result analysis
- Adaptive and predictive capabilities
- Regular monitoring for precision medicine and early treatment
- Medical AI-reasoning with medical guidance
- Smart report shows user learnt baselines and trends



# AI-driven immune system monitoring platform




# OIA's Artificial Intuitive Reasoning Technology

Current AI algorithms cannot learn some tasks that require human-like cognition, like counting, or driving a car without having to drive millions of miles

OIA's AI causal reasoning capabilities can. OIA can help find disease causes rather than matching symptoms, providing causal diagnostics.

On March 2021, OIA won **Etihad's AI International Competition** for revenue prediction against Accenture, Microsoft etc, validating OIA's AI from academia to industry

[Click here to view video:](https://youtu.be/rkmz7DAA-t8)  
<https://youtu.be/rkmz7DAA-t8>



Produced by



**nature**  
International journal of science

CONFIDENTIAL

MEDTECHAI

# Market Opportunity

Healthcare Apps Revenue




\*CBC – Complete Blood Count, also known as Full Blood Count



# Unique Position

At the intersection of **technological** and **commercial** innovation

The 23andme of the immune system but **medically-relevant** and **actionable**



Subscription  
Based  
B2B2C Markets:

Gillette “Razor-Blades”  
revenue model

ENTRY MARKET





# OIA's Milestones 1<sup>st</sup> Half 2021

since last funding round



## PRODUCT DEVELOPMENT

Device designed by award-winning (Formula 1) industrial designers.

Signed manufacturing deal to deliver first commercial device in Q4 2021

Tripled software headcount to speed up software development:

- Web-based platform in Beta
- Mobile device software in Alpha

Doubled engineering and AI teams to design and develop the AI Algocyte mobile health station evolution

Hired 2 world experts in CE and FDA regulatory approvals. First consultations with the FDA

Bought 2 reference machines from competitors for regulatory approvals (UKCA, CE and FDA 510(k))



## OIA DISEASE DATABASE

Acquired 10K longitudinal datapoints from hundreds of patients added improving our AI prediction models from 90% to 95%. OIA will reach 40K datapoints next year making OIA one of the companies with the most significant blood test data worldwide



## IP EXPANSION

Filed 4 new patents for a total of 6 protecting OIA's mobile device and consumable (disk).

First patent filed in the U.S. expected to be granted by end of year



## COMMERCIAL READINESS

Joined OIA:

- Pam Winsor (former CMO @Medtronic Canada)
- Steve Syme (former J&J, 15 devices to market)
- Allan Bezanson (leading & investor experience)
- Juan Vegarra (former Director WW S&M @Microsoft)
- Luc Bowie (former UK manager from Sight)
- S. Partha (From Indian lab leader CareData)



## OIA CELL DATABASE

Produced 10K new labelled cell images for AI training purposes and 30K more to be completed by Q4, making OIA's one of the largest cell repositories for AI training and validation



## INNOVATION + R&D BREAKTHROUGHS

Improved methods for cell detection and morphology from 80% to 90% accuracy

Won AI Etihad international prize against Accenture and Microsoft

AI modules integrated into the Algocyte platform and production-ready

Current development and integration of the adaptive and predictive modules

Device future capability expansion to immunofluorescence for antibody detection (e.g. Covid19)

# OIA's Milestones 2<sup>nd</sup> Half – 2021

since last funding round



## TRACTION IN NORTH AMERICA

Graduated from the prestigious U.S./Canada-based Creative Destruction Lab (CDL) among one other startup among 400 applicants after 5 months of intensive work with top North American leaders and investors in the health industry



## TRACTION IN INDIA

Partnership with laboratory software leader CareData to integrate Algocyte to their Laboratory Information Management System in India



## TRACTION IN MENA

Received a ~200K USD grant in kind by the Abu Dhabi government to support OIA's AI R&D and attract global talent. Only 15 companies selected from ~100 to expand in the Middle East and North African (MENA) markets

## TRACTION IN EUROPE



Graduated from prestigious Germany's Leipzig School of Management (HHL) accelerator, SpinLab, only 15 participants from about 200 applicants. We are working with a partner with a strong commercial network



## GLOBAL RECOGNITION

Won Etihad competition against Microsoft, Accenture, etc.

Selected to represent British Innovation in the Healthcare exhibition at the UK Pavilion at the World Dubai Expo 2020 (only 10 companies selected)



## PARTNERSHIPS

Signed partnerships with Medical University Khawarizmi College, MBZUAI, in progress with Oxford U. Hospital, to share data, run pilots, source talent and expand AI capabilities



## ADVISORY BOARD EXPANSION

Dr. Jason Berman, Director of the Children's Hospital of Eastern Ontario, joins OIA's Advisory Board to support expansion into North American market

# OIA's Milestones 2022

with warrant executed by Q4 2021



## PRODUCT DEVELOPMENT

Ready for partners' rollout in opportunity markets in Q2 2022 and for at-home device ready for production in H2 2022 entering markets as soon as we get the corresponding regulatory approvals.



## GRANTED PATENTS

We will be granted our first 1-2 patents in the U.S. followed by 1-2 patents in Europe. And we will file at least other 5 international patents protecting OIA's device, methods and technology (including its consumables)



## REGULATORY APPROVALS

We will receive UKCA and CE IvD approval in the UK and Europe advancing our regulatory pathway in preparation for go to market. FDA procedure will be started.



## PANDEMIC RELEVANT

At-home device aim is to provide levels of immunisation for diseases such as COVID19 (and other viruses) over time flagging when people may need another booster to mitigate infection risk



## REPOSITORY EXPANSION

We will reach at 100K cell images for healthy and pathological cases and 100K longitudinal datapoints for multiple diseases, including cancer. This will consolidate OIA as a world leading AI company for longitudinal blood-related analysis and early detection



## COMMERCIAL READINESS

Expansion of commercial capabilities hiring top regional sales directors in the selected strategic markets, namely UK, India and Canada. We will establish a licensing scheme and a network of geographically-relevant world distributors

# Path to Vision 2021 - 2022

Self-testing kits



Entry market  
Cancer patients,  
oncologists,  
hematologists

Portable  
Gen 1



Regular blood tests

+ Augmented CBC  
(coarse-grained  
resolution)

Portable  
Gen 2




+ Immunofluorescence  
(antibodies, immune  
repertoire)

At-home  
Gen 3



+ Spectroscopy (super-  
fine-grained resolution)

AI-driven dashboard  
to monitor the  
immune system  
platform



End goal target  
Everyone  
Direct to  
consumer  
(2022)

TECHNOLOGY  
ENABLERS

# MEDTECHAI



OXFORD  
**Immune**  
Algorithmics®



  
algocYTE®  
CANADA

## JOINT VENTURE: Increase value to MedtechAI

**Oxford Immune Algorithmics** has agreed to grant **MedTechAI** the Canadian rights to **AlgocYTE** In a 70% MedtechAI 30% OIA **Joint Venture**.

“**AlgocYTE Canada**” will have access to OIA management and R&D evolution.

**Hector Zenil**, CEO of OIA will join the board of “AlgocYTE Canada”.

Four-member board, two from MedTechAI one from Oxford and one independent.

# MedTechAI Financing

Use of proceeds to exercise warrants for £3 million GBP bringing MedTech ownership of OIA to 38%

MEDTECH CAPITALIZATION CHART	COMMON SHARES
Current Issued and Outstanding	66,670,477
Existing Broker Warrants	1,126,040
Capital raise at \$0.30 per common share	\$5,000,000
Shares Issued as per Current Financing	16,666,667
New Financing Broker Warrants	1,000,000
<b>Post Financing Fully Diluted</b>	<b>85,463,184</b>
<b>Post Money Market Capitalization</b>	<b>\$25,001,143</b>




# Contact Us

Scott Young

 +1-705-888-2756

 scott@medtechai.io

 www.medtechai.io



# Appendix

Patents pending:

GB1918948.9

GB2020375.8

P598865GB00

P599093GB00

P598949GB00

P598873GB00

P501233GB00PCT

GB2020/05328

# OIA Commercial Acumen

**PAM WINSOR**  
Chairwoman



Former CMO at

**Medtronic**

*World largest medical device company*

**STEVE SYME**  
Head of Operations



Former Product  
Manager & Senior  
R&D Engineer at

**Johnson & Johnson**

**INTELLIGENT  
ULTRASOUND**  
*for smarter scanning*

**DR. LIONEL KHALIL**  
Chief Financial Officer



Former Strategic  
Advisor at

**MARS**  
Tomorrow starts today

*Largest animal care services company*

**KPMG**

**JUAN VEGARRA**  
Senior VP Global BD



Former Director  
WW S&M at

**Microsoft**

**LUC BOWIE**  
UK Sales Director



Former UK Sales  
Manager at

**sight**

**stryker**

*International  
leading medical technology  
companies*

About 30 more people complete the team. 50% holds a PhD degree, 2/3 holds a Masters or MD  
~ 1/3 are women and 3/4 BAME (minorities)

CONFIDENTIAL


**MEDTECH** AI

# OIA Technical Experience

**DR. ISAAC JONES**  
Head of Product



**DR. OKSANA JOSYPCUK**  
Assay Integration Engineer



**DR. LUIS ACEVEDO**  
Optical Systems Engineer



**HARPREET KAUR SANDU**  
Scrum Master



**J. SANTIAGO ZENIL-ARAIZA**  
Team Lead Engineer



From the largest and most prestigious medical device companies

CONFIDENTIAL

MEDTECH $\Delta$ I

# MedTechAI Leadership Team

**Pamela Winsor, RN, MBA, ICD.D** - Chairwoman of the Board - Pam is a respected and highly accomplished healthcare leader in Canada. With over 20 years as a Senior Healthcare Executive (former CMO, Medtronic), Pam has a deep knowledge of the life sciences sector and what it takes to get a new technology or solution to market and to get it fully funded, even in a very restrained healthcare environment. More importantly, Pam has expertise in leading and steering the future direction of healthcare. She was one of early champions of value-based healthcare strategies and novel access approaches which simultaneously improve outcomes and lower costs. This will encompass new players/technologies, new financial models and more long-term strategic oversight, challenging legacy care models and current healthcare boards. These approaches will enrol and engage new players by adopting new technologies and financial models, thereby challenging legacy models to provide better care and sustainable long term strategic oversight.

**John Cullen - CEO & Director** - John has over 30 years experience in successful public company financing, corporate/capital structuring and management. Following 15 years in the Canadian investment industry, he has founded and profitably exited a number of private and public companies. Many of the companies have international businesses across various industry sectors. He has a track record in creating accretive value to shareholders. At present, he is also the CEO & Director of the Board of JHI Associates Inc, an exploration company partnered with Exxon and Total in a deepwater offshore petroleum exploration block in Guyana South America. Industry agnostic, John has demonstrated the ability to provide leadership and vision across different sectors.

**Allan Bezanson – Director** - Allan is currently the Chair of the Board, BW Founders Holdings Ltd. (a company owned by his family trust). He is an active investor, primarily in technology and oil and gas with an astute knowledge of the capital markets from both the buy and sell perspectives. Seasoned director at a number of private companies, Allan honed his skills and strategic acumen by having played key roles and/or held executive positions at hedge funds, private equity and financial services. Allan's early career was at Nowsco Well Service Ltd., where he spearheaded the financing and structuring of the international operations in over a dozen countries. In the late nineties, he managed over \$1B AUM of arbitrage assets at an offshore hedge fund. More recently he has spent time financing and advising a number of private and public entities resulting in notable success; specifically: Nowsco Well Service, Altus, Bluewave Energy, FCF Capital, Polaris Infrastructure and Voxtur. Throughout his distinguished career, Allan has lived and worked in the Netherlands, Guernsey, Barbados, United States of America, and Canada.

# MedTechAI Leadership Team

**Andres Tinajero- CFO** - Andres has a diverse background working in the last 2 decades in a broad range of industries, including technology, oil and gas, mining and manufacturing. He has been played key roles in financing strategy and planning, joint ventures, mergers, acquisitions and financial control. Detail-oriented and strategic, he has added significant value serving as CFO and/or VP Finance for several public companies.

**Scott Young - VP, Corporate Development** - Scott has an extensive background in corporate development, fundraising strategy and tactical planning. Companies he has successfully helped fund are in diverse industries such as biotech, medtech and natural resources. He has a comprehensive institutional financing network that spans North and South America, Europe and Asia. He has delivered investment results for various private or public entities. His track record of delivering value has been consistent for over 2 decades.

**Wendy T. Chan, BSc, MBA, ICD.D - Vice President, Strategy** - Wendy is a Director of Moxie Strategy, Inc., a consulting firm that specializes in Strategy, Business Development, Joint Ventures, Mergers and Acquisitions. She is the Founder and former Director of Carepoint Medical & Wellness Clinics, a chain of primary and specialist care clinics in British Columbia. Previously she had profitably managed, with full P&L responsibilities, over a dozen multi-million businesses at Fortune 500 healthcare companies such as: Johnson & Johnson (J&J), Glaxo-SmithKline(GSK), Ortho-McNeil(Janssen). At J&J, she was the Canadian Lead and Business Director, managing a product portfolio of Diagnostic Test Kits, OTC Contraceptives and Prophylatics. She has a Medical Science undergraduate degree from the University of British Columbia, with directed studies on SSRI's & Depression, an MBA in Finance and Marketing from McGill University and she has recently received ICD.D Designation at Rotman Institute of Corporate Directors, University of Toronto. Previously, Wendy served as a Director of the Board at the British Columbia Cancer Foundation, and as an advisory and committee member at the Heart and Stroke Foundation, Vancouver Opera, and Women in Leadership. She is also the Founder of the University of British Columbia Badminton Club.



# Strategic Partnerships & Endorsements

## OXFORD IMMUNE ALGORITHMICS IS

*On the leading edge of this “self-administered” diagnostics trend and is helping to shape it*

## WITH THEIR AT-HOME DIAGNOSTICS...

Richard Foster  
Chairman of the Medical Research  
Committee of the W. M. Keck Foundation,  
and member of the Board of Memorial  
Sloan Kettering Cancer Center

This [OIA/ALGOCYTE] is a rockstar team!

### ... BASED ON

*Sustantial amount of proprietary AI algorithms developed for the problem at hand by people with ample expertise.*

Dr. Inmar Givoni  
Director Of (AI) Engineering, Uber

From an independent report commissioned by the Creative Destruction Lab in the U.S. (exclusive and leading accelerator) for their selection process

CONFIDENTIAL

MEDTECHAI

# Validation, Market Strategy

Co-developing, testing and commercial agreement with

# NHS

Britain's National Health System



U.K. Reseller

Leader in the hematology market in  
the UK (1/3 of the market)



U.K. Adopter

Ten houses to open in Q1 2021 in Surrey  
with Algocyte 'embedded' in the  
intelligent home system

CONFIDENTIAL

MEDTECHAI

# 2020 -2021 Awards



February 3, 2020

OXFORD IMMUNE ALGORITHMICS IS CHOSEN AS ONE OF THE 50 MOST PROMISING GAME-CHANGERS IN THE THAMES VALLEY IN THE UK



June 15, 2020

OXFORD IMMUNE ALGORITHMICS IS NOMINATED FOR THE BEST START-UP MEDTECH AWARD 2020 BY OBN



March 18, 2021

OXFORD IMMUNE ALGORITHMICS announced the winner of Etihad's AI international competition.

# OIA's International Traction

## Middle East & Africa

# HUB71

OIA UAE branch sponsored by the UAE committed to invest and grow the company as a hub for Asia, Africa and the Middle East. Signed collaboration agreement with medical university (KIC)

## U.S.



OIA is one of 3 finalists among 400 startups. MedtechAI Agreement to invest up to £ 5M in OIA in the next 2 years. Pam Winsor CMO of Medtronic joining board.

## China

# Sinldo 芯联达

Signed Letter of Intent. Leading IT remote/mobile healthcare solution provider in China covering 1K hospitals with over 600m patient visits a year and 1.5m doctors. They want 3K devices to begin with

## Germany & EU



SpinLab's and Leipzig's commercial partners and support to open European branch. Agreement with the Leipzig zoo to test our technology applied to vet

## U.S.



Servicing 40 hospitals. Terms agreed to integrate Algocyt in their pathology pathway offerings